A hope for neurodevelopmental dysfunctions

IAMA Therapeutics, a start-up company that will develop a new drug candidate for neurodevelopmental dysfunctions such as autism spectrum disorders, is underway. It stems from the work of two research groups of the ITALIAN INSTITUTE OF TECHNOLOGY (IIT) of Genoa: “Brain Development and Disease” and “Molecular Modeling and Drug Discovery”, led respectively by scientists Laura Cancedda and Marco De Vivo. The project, supported by the Telethon Foundation, was financed by Claris Ventures Sgr and CDP Venture Capital Sgr through its Evolution Fund. Clinical trials of the potential drug called IAMA-6 will begin in the next 24 months. Read the Telethon article “IAMA Therapeutics is underway, to develop a new drug candidate for neurodevelopmental dysfunctions“.